Lung cancer is the second most common cancer worldwide and the leading cause of cancer deaths. Nearly 80% of patients with lung cancer present with regional or metastatic disease at diagnosis, which is associated with poor prognosis. Conventional treatment strategies mainly include surgery, chemotherapy and radiotherapy. In the last decade, emerging immunotherapy and targeted therapies are rapidly shaping the treatment landscape. Current guidelines recommend immune checkpoint inhibitors for eligible patients with metastatic non-small cell lung cancer. In addition, several immune checkpoint inhibitors for the treatment of lung cancer have demonstrated promising efficacy in clinical trials. However, in many cases, the clinical benefit from these therapies is limited, with the majority of patients not able to achieve durable remission. Also, immune-related adverse events, lack of predictive biomarkers and criteria for patient selection represent some of the key challenges remain to be addressed for the broader application of immunotherapy in lung cancer treatment. Therefore, further research is needed for a better understanding of immunotherapies and how to best combine conventional treatment with immunotherapy, in order to optimize the current treatment strategies and improve clinical outcome.
The Research topic aims identify novel immunotherapeutic targets and improve multimodality therapy for lung cancer. We also aim to report safety profile of immunotherapy and provide a reference basis for the rational. We also wish to explore the impacts of the tumor microenvironment on immunotherapy of lung cancer, and improve the clinical use of immunotherapy drugs for lung cancer treatment. Finally, we aim to exploit and identify biomarkers for predicting immunotherapy response and prognosis.
We welcome submissions of Original Research, Clinical Trial, Methods, Case Report, Systematic Reviews, Reviews, and Mini-Reviews focusing on lung cancer, covering but not limited to the below aspects:
1. Identification of novel immunotherapeutic targets for lung cancer
2. Improvements of multimodality therapy for lung cancer
3. Safety profile, including report of adverse events of immunotherapy in lung cancer
4. Identification of biomarkers for predicting immunotherapy response and prognosis
5. Impacts of the tumor microenvironment on immunotherapy of lung cancer
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation are considered out of scope of this section.
Lung cancer is the second most common cancer worldwide and the leading cause of cancer deaths. Nearly 80% of patients with lung cancer present with regional or metastatic disease at diagnosis, which is associated with poor prognosis. Conventional treatment strategies mainly include surgery, chemotherapy and radiotherapy. In the last decade, emerging immunotherapy and targeted therapies are rapidly shaping the treatment landscape. Current guidelines recommend immune checkpoint inhibitors for eligible patients with metastatic non-small cell lung cancer. In addition, several immune checkpoint inhibitors for the treatment of lung cancer have demonstrated promising efficacy in clinical trials. However, in many cases, the clinical benefit from these therapies is limited, with the majority of patients not able to achieve durable remission. Also, immune-related adverse events, lack of predictive biomarkers and criteria for patient selection represent some of the key challenges remain to be addressed for the broader application of immunotherapy in lung cancer treatment. Therefore, further research is needed for a better understanding of immunotherapies and how to best combine conventional treatment with immunotherapy, in order to optimize the current treatment strategies and improve clinical outcome.
The Research topic aims identify novel immunotherapeutic targets and improve multimodality therapy for lung cancer. We also aim to report safety profile of immunotherapy and provide a reference basis for the rational. We also wish to explore the impacts of the tumor microenvironment on immunotherapy of lung cancer, and improve the clinical use of immunotherapy drugs for lung cancer treatment. Finally, we aim to exploit and identify biomarkers for predicting immunotherapy response and prognosis.
We welcome submissions of Original Research, Clinical Trial, Methods, Case Report, Systematic Reviews, Reviews, and Mini-Reviews focusing on lung cancer, covering but not limited to the below aspects:
1. Identification of novel immunotherapeutic targets for lung cancer
2. Improvements of multimodality therapy for lung cancer
3. Safety profile, including report of adverse events of immunotherapy in lung cancer
4. Identification of biomarkers for predicting immunotherapy response and prognosis
5. Impacts of the tumor microenvironment on immunotherapy of lung cancer
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation are considered out of scope of this section.
